News

Date Title View
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business and Product Development Update
Focused on Building a Major Ophthalmic Pharmaceutical Company Rhopressa TM and Roclatan TM Development Programs Advancing Conference Call and Webcast Today, November 11 , at 5:00 p.m. ET BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its third quarter 2014 financial results will be released after the market closes on Tuesday, November 11, 2014 .
View HTML
Toggle Summary Aerie Pharmaceuticals Elects Benjamin F. McGraw, III to Its Board of Directors
BEDMINSTER, N.J. , RESEARCH TRIANGLE PARK, N.C. , & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that
View HTML
Toggle Summary Aerie Announces Closing of $125 Million Convertible Notes Financing
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it
View HTML
Toggle Summary Aerie Announces $125 Million Convertible Notes
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it
View HTML
Toggle Summary Aerie Pharmaceuticals to Host Investor Day on September 10, 2014
-Webcast to Begin at 12:00p.m. Eastern time - BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that the Company will host a live webcast in conjunction with its Investor Day on Wednesday, September
View HTML
Toggle Summary Aerie Pharmaceuticals Inc. Initiates Phase 3 Safety-Only Registration Trial in Canada of RhopressaTM in Patients with Glaucoma
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Canaccord Genuity 34th Annual Growth Conference
BEDMINSTER, N.J. , RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido , Jr., Ph.D., chairman and chief executive officer will present at the Canaccord Genuity 34th Annual Growth Conference on
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Business and Product Development Update
Rhopressa TM Phase 3 Registration Trials Have Commenced, Three-Month Efficacy Results Expected Mid-2015; Potential to File New Drug Application by Mid-2016 After Successful Phase 2b Results, Roclatan TM Phase 3 Enabling Activities in Progress Conference Call and Webcast Today, August 6 , at 5:00
View HTML
Toggle Summary Aerie Pharmaceuticals, Inc. Receives Health Canada "No Objection Letter" to Commence Phase 3 Registration Trial of RhopressaTM in Patients with Glaucoma in Canada
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that it
View HTML